Rochester, NY 9/1/2009 1:25:44 PM
Johnson & Johnson JNJ, Up 0.25% at the end of the market trade
Johnson & Johnson
Johnson & Johnson company announced that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER Sirolimus-eluting Coronary Stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, AK. CYPRESS will provide data to support the clinical evaluation of the company`s new NEVO Sirolimus-eluting Coronary Stent in the NEVO III trial, a non-randomized, single-arm trial evaluating the clinical outcomes of NEVO in approximately 1,200 patients in the United States and Canada. NEVO is the first drug-eluting stent utilizing RES TECHNOLOGY, which incorporates hundreds of small reservoirs, each acting as a depot into which drug-polymer compositions are loaded. The patients in this study will represent a variety of coronary artery disease cases including those considered `complex` due to multi-vessel disease.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to BOTTOM of this page for free stock alerts, or visit our site.
Last Trade: 60.44
Day's Range: 59.96 - 60.59
52wk Range: 46.25 - 72.76
Change: Up 0.15 (0.25%)
Volume: 10,181,307
Avg Vol (3m): 12,061,000
About Johnson & Johnson JNJ
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. Johnson & Johnson has more than 250 operating companies. The Company operates in three segments. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women’s healthcare fields, as well as nutritional and over-the-counter pharmaceutical products. The Pharmaceutical segment includes products in the therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers. In July 2009, Johnson & Johnson completed the acquisition of Cougar Biotechnology, Inc. with approximately 95.9% interest in Cougar Biotechnology's outstanding common stock.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.
